<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pharmaceuticals-12-00157-t006" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pharmaceuticals-12-00157-t006_Table 6</object-id>
 <label>Table 6</label>
 <caption>
  <p>Anti-ZIKV compounds having the potential to be drugs.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Derivatives</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroquine</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Derivatives particularly at the C-4 position of 
     <italic>N</italic>-(2-arylmethylimino)ethyl-7-chloroquinolin-4-amine derivatives
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B98-pharmaceuticals-12-00157" ref-type="bibr">98</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Quinacrine (QC), Mefloquine (MQ), and GSK369796</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Antimalarial aminoquinoline derivatives</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B41-pharmaceuticals-12-00157" ref-type="bibr">41</xref>,
     <xref rid="B87-pharmaceuticals-12-00157" ref-type="bibr">87</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PHA-690509</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyclin dependent kinase (CDK) inhibitor</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B99-pharmaceuticals-12-00157" ref-type="bibr">99</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Lapachol, HMC-HO1α and Ivermectin</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Hybrid drugs against co-infections of ZIKV, dengue and chikungunya</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B100-pharmaceuticals-12-00157" ref-type="bibr">100</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">20-Cmethylated nucleosides</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inhibitors of RNA-dependent RNA polymerase (RdRp)</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B101-pharmaceuticals-12-00157" ref-type="bibr">101</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">NS3 inhibitors</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Covalent inhibitors of a viral protein and anti-Toll-like receptor molecules</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B102-pharmaceuticals-12-00157" ref-type="bibr">102</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved drugs</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In vitro screening of 774 compounds led to twenty compounds that were found to reduce ZIKV infection</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B93-pharmaceuticals-12-00157" ref-type="bibr">93</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">NIH clinical library of compounds</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">By screening 725 chemically diverse compounds from the library, 22 compounds were reported to have potent anti-ZIKV activity of which five were found promising. These are Lovastatin (Pubchem CID: 53232), 5-Fluorouracil (Pubchem CID: 3385); 6-Azauridine (Pubchem CID: 5901); Palonosetron (Pubchem CID: 6337614) and Kitasamycin (Pubchem CID: 44634697).</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B103-pharmaceuticals-12-00157" ref-type="bibr">103</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">A limited proprietary library of small organic compounds</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Anti-ZIKV activity through screening and confirming potent anti-ZIKV activity in in vitro plaque assay</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B104-pharmaceuticals-12-00157" ref-type="bibr">104</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">NITD008</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">A type of nucleoside adenosine analog</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B105-pharmaceuticals-12-00157" ref-type="bibr">105</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Warfarin and a few similar structural analogues</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inhibitors of dimerization of Axl receptor (a tyrosine kinase)</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B106-pharmaceuticals-12-00157" ref-type="bibr">106</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, ibuprofen, naproxen, acetaminophen, and lornoxicam, potently inhibited the entry of Zika virus Env/HIV-1-pseudotyped viruses </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Inhibited replication of wild-type ZIKV both in cell lines and in primary human fetal endothelial cells. Interestingly, the NSAIDs exerted this inhibitory effect by potently reducing the expression of AXL, the entry cofactor of ZIKV. Further studies showed that the NSAIDs downregulated the prostaglandin E
     <sub>2</sub>/prostaglandin E receptor 2 (EP2)/cAMP/protein kinase A (PKA) signaling pathway and reduced PKA-dependent CDC37 phosphorylation and the interaction between CDC37 and HSP90, which subsequently facilitated CHIP/ubiquitination/proteasome-mediated AXL degradation.
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B107-pharmaceuticals-12-00157" ref-type="bibr">107</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanchangmycin</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Envelope glycoprotein inhibitor</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B90-pharmaceuticals-12-00157" ref-type="bibr">90</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Temoporfin, NSC157058</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">NS2B-NS3protease inhibitors</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B108-pharmaceuticals-12-00157" ref-type="bibr">108</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Suramin</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NS3 polymerase inhibitors</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B109-pharmaceuticals-12-00157" ref-type="bibr">109</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Sofosbuvir, 2′-C-ethynyl-UTP and DMB213</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">NS5 polymerase inhibitors</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B110-pharmaceuticals-12-00157" ref-type="bibr">110</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sinefungin</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NS5 methyltransferase inhibitor</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B111-pharmaceuticals-12-00157" ref-type="bibr">111</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">6-azauridine and 5-fluorouracil</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Pyrimidine biosynthesis inhibitors</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B93-pharmaceuticals-12-00157" ref-type="bibr">93</xref>,
     <xref rid="B95-pharmaceuticals-12-00157" ref-type="bibr">95</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lovastatin and Mevastatin</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HMG-CoA reductase inhibitor</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B112-pharmaceuticals-12-00157" ref-type="bibr">112</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCX4430 </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An adenosine nucleoside analog, functions as a selective inhibitor of viral RNA-dependent RNA polymerase (RdRp). It was found that BCX4430 had EC
     <sub>50</sub> values in the range 3.8–18.2 μg/mL in vitro, with favorable selective index (SI) values. In a mouse model of ZIKV infection (300 mg/kg/d), treatment with BCX4430 showed promising results. The protective effect of BCX4430 was observed to continue for 24 h even after virus challenge.
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B113-pharmaceuticals-12-00157" ref-type="bibr">113</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
